Time New York: Sun 18 Nov 05:42 am  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

Is Allergan (AGN) a Great Stock for Value Investors?

Zacks

Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?

One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Allergan plc AGN stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:

PE Ratio

A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.


On this front, Allergan has a trailing twelve months PE ratio of 11.1, as you can see in the chart below:

This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 19.9x. If we focus on the long-term PE trend, Allergan’s current PE level puts it below its midpoint over the past five years, with the number having risen rapidly over the past few months.

However, the stock’s PE compares unfavorably with its industry’s trailing twelve months PE ratio, which stands at 9.7. At the very least, this indicates that the stock is relatively overvalued right now, compared to its peers.

We should also point out that Allergan has a forward PE ratio (price relative to this year’s earnings) of just 11.7, which is tad higher than the current level. So, it is fair to expect an increase in the company’s share price in the near term.

P/S Ratio

Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.

Right now, Allergan has a P/S ratio of about 3.9. This is higher than the S&P 500 average, which comes in at 3.5x right now. Also, as we can see in the chart below, this is well below the highs for this stock in particular over the past few years.

If anything, AGN is in the lower end of its range in the time period from a P/S metric, suggesting some level of undervalued trading—at least compared to historical norms.

Broad Value Outlook

In aggregate, Allergan currently has a Value Score of B, putting it into the top 40% of all stocks we cover from this look. This makes Allergan a solid choice for value investors, and some of its other key metrics make this pretty clear too.

What About the Stock Overall?

Though Allergan might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of D and a Momentum Score of B. This gives AGN a Zacks VGM score — or its overarching fundamental grade — of C. (You can read more about the Zacks Style Scores here >>)

Meanwhile, the company’s recent earnings estimates have been upbeat. The current quarter has seen sixteen estimates go higher in the past sixty days compared to four lower, while the full year estimate has seen nineteen up and two down in the same time period.

This has had just a small impact on the consensus estimate though as the current quarter consensus estimate has increased by 2.1% in the past two months, while the full year estimate has increased by 1.3%. You can see the consensus estimate trend and recent price action for the stock in the chart below:

Allergan plc Price and Consensus

Allergan plc Price and Consensus | Allergan plc Quote

The stock has just a Zacks Rank #3 (Hold) and we are looking for in-line performance from the company in the near term.

Bottom Line

Allergan is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. However, with a sluggish industry rank (among Bottom 41% of more than 250 industries) and a Zacks Rank #3, it is hard to get too excited about this company overall. In fact, over the past two years, the broader industry has clearly underperformed the market at large, as you can see below:

So, value investors might want to wait for estimates and analyst sentiment to turn around in this name first, but once that happens, this stock could be a compelling pick.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.